PW Consulting Release: Strategic Preview — Pulmonary Function Testing Systems Market Outlook and Decision Framework for 2026

PW Consulting’s new market study on Pulmonary Function Testing (PFT) Systems — with base year 2025 and a forecast horizon through 2032 — delivers the decision-grade intelligence executive teams need to prioritize investment, product and commercial strategies in 2026. Our high-level briefing below summarizes the report’s most consequential market signals and strategic levers, while intentionally withholding the detailed subsegment tables and regional breakdowns to preserve the full analytical value for subscribers.
Pulmonary Function Testing Systems Market

Market trajectory and what it means for 2026 planning

The PFT systems market has demonstrated steady expansion during the 2020–2025 historical window and enters 2026 from a position of strength. Measured in USD Million, the market’s base-year value (2025) establishes the platform from which our forecast projects a compound annual growth rate (CAGR) of 6.8% through 2032. Under that trajectory, the global market is expected to approach roughly USD 5.95 billion by the end of the forecast period.
Pulmonary Function Testing Systems Market

Two simple takeaways for leadership teams:
Pulmonary Function Testing Systems Market

• Growth is durable but selective. Overall market growth creates capacity for new entrants and adjacent-product investment, yet returns will concentrate around differentiated technology, integrated workflows and validated clinical outcomes.
• Timing matters in 2026. With a mid-single-digit CAGR, first-mover advantages in product upgrades, regulatory readiness and channel partnerships will compound over the forecast period — delaying action dilutes ROI.

Market structure and competitive dynamics

Our analysis shows the PFT market remains fragmented: the three largest vendors account for less than one-quarter of industry revenue, and the five largest account for roughly a quarter. This low concentration profile creates dual strategic realities. On the one hand, incumbents face continuous pressure from specialist innovators (compact, software-enabled devices and cloud-enabled services). On the other, there is substantial runway for consolidation and scale-based advantage, particularly for organizations that can combine product portfolios with distribution reach or ancillary software services.

Key vendors profiled in the report include established clinical-system manufacturers and newer, device-focused innovators. Representative profiles and recent moves highlight strategic vectors we expect to influence competitive outcomes in 2026:

• Vitalograph (UK) — a long-standing developer of professional PFT platforms and oscillometry solutions. Recent strategic partnerships aim to broaden diagnostic scope, underlining the company’s playbook of technology alliances to enter adjacent diagnostic use-cases.
• Jaeger Medical (Germany) — known for PC-based diagnostic suites for lab and clinical settings. Their positioning reflects the premium, lab-grade segment where integration with hospital information systems and certified performance are purchase drivers.
• MGC Diagnostics (USA) — with an emphasis on integrated software platforms and cardiopulmonary exercise testing, their strength is in end-to-end diagnostic workflows for hospital systems.
• Norav Medical (USA/Germany) — focused on ultra-compact, USB-powered spirometers designed for clinical and point-of-care contexts; product launches in 2025 emphasize portability and regulatory-compliant device design.
• MIR Medical International Research (Italy/NA) — a cross-border player targeting smart, smartphone-compatible PFT devices suitable for clinical and home-monitoring scenarios.

Recent, illustrative developments in the field reinforce these trends:

• Partnerships to expand diagnostic breadth and oscillometry offerings were announced at major respiratory summits in 2025.
• Compact, standards-certified spirometer product launches in late 2025 signal continued investment in portable, clinician-grade devices.
• FDA 510(k) clearances for integrated measurement platforms indicate growing interest in multi-modal diagnostic devices that combine pulmonary metrics with cardiac monitoring for clinical-trial and hospital use.

Regulatory, standards and reimbursement context — operational constraints for 2026

For product, regulatory and procurement teams, the operational environment is not an afterthought — it is a determinant of speed-to-market and contracting success.

• Regulatory: In the EU, pulmonary function equipment is treated as diagnostic respiratory devices under the Medical Device Regulation (EU MDR 2017/745), with stricter clinical evaluation and notified-body oversight. This raises time and cost for European market entry and post-market surveillance programs.
• Standards: Compliance with relevant international standards (including ISO standards governing occupational spirometry and lung-volume measurement) is a procurement precondition for many institutional buyers and multinational tenders.
• Clinical accreditation and device lifecycle processes: Joint Commission and similar accrediting bodies mandate documented cleaning, disinfection and sterilization procedures for reusable PFT equipment — an important operational constraint for hospitals and outpatient clinics.
• Reimbursement: Fee-schedule realities influence purchaser economics. For example, commonly used PFT CPT codes have fixed reimbursement benchmarks that constrain billing uplift from incremental device features; therefore, commercial strategies must combine device sales with service and software models to capture greater lifetime value.

Where value will accrue in 2026 — strategic opportunity map

Our market modeling and buyer-behavior research point to a set of high-impact opportunity clusters for 2026 investment and execution:

• Software-enabled clinical workflows: Integrations that reduce staff time per test, enable centralized quality-control and provide cloud-based analytics will command premium pricing and promote account stickiness.
• Portability with professional accuracy: Products that combine the convenience of compact hardware with lab-grade validation and multi-standard certifications will accelerate adoption in point-of-care and decentralized settings.
• Services and subscription bundles: Given constrained reimbursement levels for discrete PFT CPT codes, vendors can augment device revenue with managed services (calibration, training, software licenses and outcome analytics) to build recurring revenue.
• Regulatory-first design: Designing products and clinical evidence plans around MDR and ISO expectations reduces time-to-contract in regulated markets and limits post-market compliance costs.
• M&A and licensing plays: Fragmentation in supplier landscapes suggests active consolidation opportunities for players seeking volume, distribution or complementary product capabilities.

Report content — what PW Consulting delivers to decision-makers

The full market report is designed as an execution toolkit for executives and investment committees. It contains:

• Proprietary historical and forecast market sizing (base year 2025; forecast through 2032) with scenario analysis to stress-test demand under different clinical-adoption and regulatory timelines.
• Detailed competitor profiles and capability maps (product portfolios, clinical validation status, distribution models and R&D pipelines) for the leading and emerging vendors.
• Commercial playbooks — go-to-market segmentation, pricing approaches that compensate for reimbursement ceilings, and service models that increase lifetime value.
• Regulatory and standards playbook — checklists and timelines for EU MDR, FDA pathways and international ISO conformance, including examples of clinical-evidence strategies that reduce approval risk.
• Procurement and deployment templates for hospitals and large clinic networks that help purchasing teams evaluate total cost of ownership, infection-control logistics and integration with EMR systems.
• Investment and M&A guidance — valuation considerations, integration risks, and accretion/dilution modeling under different acquisition scenarios.

Note: To preserve competitive value, this briefing omits the detailed subsegment tables (regional splits, device-type revenue line-items and application-specific values) that form the core analytical IP of the full report. Those datasets and interactive models are available to subscribers and clients via our website and bespoke advisory engagements.

Action checklist for executives entering 2026

Use the following prioritized actions to convert market insight into results during 2026:

• Accelerate regulatory readiness: Incorporate MDR and ISO compliance into product roadmaps now to avoid commercialization delays in major markets.
• Differentiate on software and workflow efficiency: Prioritize clinical-validation projects that quantify time savings and diagnostic accuracy improvements for buyers.
• Design hybrid commercial models: Blend device sales with recurring software/service contracts to offset reimbursement constraints and improve customer retention.
• Scan for bolt-on acquisition targets that add distribution reach or complementary technologies (oscillometry, integrated ECG, cloud analytics).
• Engage early with large system buyers to pilot bundled offerings that combine devices, training and remote QA services — pilots can unlock preferred-supplier status for multi-year contracts.

Final word — why this matters for 2026

As the PFT systems market expands at an anticipated 6.8% CAGR from the 2025 base, the next 12–18 months will determine which vendors convert growth into enduring advantage. Fragmentation signals opportunity, but successful players will be those that combine certified clinical performance, regulatory foresight, software-enabled workflow improvements and recurring revenue models. PW Consulting’s full report equips executive teams with the datasets, competitor intelligence and tactical playbooks required to make high-confidence decisions in 2026. For access to the complete subsegment analysis, interactive models and vendor benchmarking, visit PW Consulting or contact our advisory team for a tailored briefing.

For detailed analysis of this topic, please visit the official page: Pulmonary Function Testing Systems Market

Lacy Lee
Senior Marketing Manager
sales@pmarketresearch.com
00852-95632430
PW Consulting: www.pmarketresearch.com